Table 2.

Minimal and multivariable adjusted odds ratios for the development of rapid decline in eGFR, incident stage 3 CKD, and incident microalbuminuria

	ABI >1.1-<1.4	p	ABI >0.9-1.1	p	ABI ≤0.9	p	P****
Rapid eGFR decline
No. Events/No. at Risk	129/1719		88/822		15/51
Baseline age, sex, and eGFR-adjusted*	1.0 (ref)	-	1.43 (1.04-1.97)	0.03	5.73 (2.77-11.85)	<0.001	<0.001
Multivariable-adjusted**	1.0 (ref)	-	1.33 (0.95-1.92)	0.09	3.60 (1.65-7.87)	0.001	0.003
Incident Stage 3 CKD***
No. Events/No. at Risk	158/1634		97/ 751		15/41
Baseline age, sex, and eGFR-adjusted*	1.0 (ref)	-	1.17 (0.86-1.60)	0.3	2.51 (1.16-5.44)	0.02	0.04
Multivariable-adjusted**	1.0 (ref)	-	1.06 (0.77-1.47)	0.7	1.68 (0.75-3.76)	0.2	0.4
Incident Microalbuminuria
NO. Events/No. at Risk	116/1295		66/584		7/23
Baseline age, sex, and ln(UACR)-adjusted	1.0 (ref)	-	1.43 (1.01-2.03)	0.05	2.81 (1.07-7.37)	0.04	0.009
Multivariable-adjusted**	1.0 (ref)	-	1.32 (0.93-1.89)	0.2	1.88 (0.68-5.15)	0.1	0.07

Note: unless otherwise indicated, values shown are odds ratio (95% confidence interval).

Abbreviations: ABI, ankle brachial index; CKD, chronic kidney disease; CI, confidence interval; eGFR, estimated glomerular filtration rate; ln(UACR), natural log-transformed urinary albumin-creatinine ratio.

^*eGFR estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Study Equation

^**Adjusted for baseline age, sex, eGFR (for rapid eGFR decline and stage 3 CKD), ln(UACR) (for microalbuminuria) and additionally for the following baseline Exam 6 covariates: body mass index, current smoking, diabetes, hypertension, high-density lipoprotein cholesterol

^***Defined as an eGFR < 60mL/min/1.73m² at end of follow-up in those with eGFR≥60mL/min/1.73m² at baseline

^****P for trend.